Skip to main content
NANJING MEDLANDER MEDICAL TECHNOLOGY CO.,LTD. logo

NANJING MEDLANDER MEDICAL TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 688273 ISIN · CNE100005PV8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 423 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688273

About NANJING MEDLANDER MEDICAL TECHNOLOGY CO.,LTD.

https://www.medlander.com/

Nanjing Medlander Medical Technology Co., Ltd. specializes in the research, development, and manufacturing of medical equipment for pelvic floor rehabilitation and reproductive health. The company provides integrated solutions featuring biofeedback and neuromuscular electrical stimulation systems, postpartum recovery devices, and specialized clinical software. Its product range addresses pelvic floor dysfunction, gynecological rehabilitation, and maternal health through non-invasive therapeutic technologies. Medlander combines advanced hardware with data-driven diagnostic tools to support healthcare providers in delivering precise treatments. In addition to clinical systems, the company offers home-use rehabilitation devices and professional training programs. By focusing on the intersection of medical engineering and clinical application, Medlander facilitates comprehensive health management and improved patient outcomes in specialized care settings.

Recent filings

Filing Released Lang Actions
北京市中伦律师事务所关于南京麦澜德医疗科技股份有限公司差异化分红事项的法律意见书
Regulatory Filings Classification · 75% confidence The document is a standalone legal opinion letter provided by a law firm regarding the company’s differentiated dividend distribution plan. It does not contain financial statements or performance data itself, nor is it announcing board changes, dividends directly to shareholders, or any M&A action. It is essentially a certification/legal counsel opinion to be attached to the company’s filings. Under the certification rule, such attestation letters fall under general Regulatory Filings (RNS).
2026-05-19 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 85% confidence The document is an announcement of the company’s 2025 annual equity distribution (cash dividend) including per‐share dividend, record date, ex‐date, payment date, distribution plan details, and tax treatment. This matches the “Notice of Dividend Amount” category.
2026-05-19 Chinese
北京市中伦律师事务所关于南京麦澜德医疗科技股份有限公司2025年年度股东会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2025 Annual General Meeting (AGM) of Nanjing Mailande Medical Technology Co., Ltd. It details the legality and validity of the AGM's convening, attendance, voting procedures, and results. It does not contain financial statements or detailed financial performance data but focuses on the procedural and legal aspects of the AGM. This matches the description of 'AGM Information' filings, which include presentations and materials shared during the AGM or related legal opinions. The document length is about 3,071 characters, which is consistent with a detailed legal opinion rather than a full annual report or other financial filings. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-05-07 Chinese
第二届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 17th meeting of the second board of directors of Nanjing Mailande Medical Technology Co., Ltd. It includes approvals of various reports such as the 2025 annual report, independent director reports, audit committee reports, internal control evaluation, profit distribution plan, and the 2026 first quarter report. It also covers approval of remuneration plans for directors and senior management, transfer of subsidiary shares, daily related party transaction estimates, use of idle funds, credit line applications, and other governance matters. The document is a formal board meeting resolution announcement, not the reports themselves but references them and states that the full reports are disclosed on the Shanghai Stock Exchange website. The document is over 7,000 characters and contains substantive content about board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. It is not an Annual Report (10-K) or Interim Report (IR) because it does not contain the full financial statements or detailed financial data, but rather resolutions approving such reports and other board matters. It is not a Regulatory Filing (RNS) because it is a formal board meeting resolution announcement with substantive content. Therefore, the correct classification is MANG with high confidence.
2026-04-15 Chinese
2025年度独立董事述职报告（舒柏晛）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 from a specific company. It details the independent director's qualifications, attendance at meetings, exercise of duties, communication with auditors and shareholders, and overall evaluation of the company's governance and operations during the year. It does not contain financial statements or quarterly/annual financial results, nor is it an announcement of voting results or management changes. It is a detailed report on the independent director's activities and governance role, which fits the category of Board/Management Information (MANG). The document length is 4104 characters, which is relatively short but contains substantive content about board activities rather than just an announcement or certification. Therefore, the best classification is MANG with high confidence.
2026-04-15 Chinese
2025年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度募集资金存放与实际使用情况的专项报告" which translates to "2025 Annual Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their storage, usage, investment projects, and compliance with regulatory rules related to raised funds. It includes detailed financial figures about the raised funds, their usage, and management, as well as auditor and sponsor opinions on the compliance and use of these funds. The document is a specialized report focusing on the use of capital raised by the company, not a general annual report or earnings release. This type of report corresponds to a Capital/Financing Update (CAP) as it provides updates on the company's fundraising and the use of those funds. The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2026-04-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.